Sermorelin UK 2026 Research Reference: Native GHRH(1-29), Pharmacology, Paediatric Trial History and Modern Research Role

Last updated: April 2026 · UK research-grade reference · For laboratory research use only — not for human consumption

Table of Contents

• 1. Overview — why sermorelin remains mechanistically important
• 2. Molecular structure: the 1-29 fragment
• 3. GHRH receptor pharmacology
• 4. Pharmacokinetics and the 10-minute half-life
• 5. Geref clinical history
• 6. Paediatric growth hormone deficiency trials
• 7. Adult GH axis research
• 8. Pulsatility preservation — the core research use
• 9. Sermorelin vs CJC-1295 vs tesamorelin
• 10. Combined protocols with ghrelin-mimetics
• 11. Safety profile and tolerability
• 12. Reconstitution, storage and stability
• 13. Modern research protocol design
• 14. UK research-grade sourcing standards
• FAQ
• References

1. Overview — why sermorelin remains mechanistically important

Sermorelin is the first-generation GHRH analogue and the mechanistic reference molecule against which all subsequent GHRH-based secretagogues (CJC-1295 no-DAC, CJC-1295 with DAC, tesamorelin) are compared. As the unmodified 29-amino-acid N-terminal fragment of native human GHRH, it exhibits identical receptor pharmacology to full-length GHRH(1-44) but with the liability of rapid DPP-4 cleavage at position 2 (Ala), giving a plasma half-life of only 10-20 minutes.

In modern UK laboratory research, three factors justify continued use of sermorelin despite the availability of longer-acting analogues: (1) it is the only widely-available GHRH analogue that reproduces the exact pharmacological profile of native GHRH without engineered modifications; (2) its very short half-life produces sharp, isolated GH pulses ideal for pulse-kinetic research; (3) it has the largest historical clinical evidence base of any GHRH analogue for paediatric GH axis research.

2. Molecular structure: the 1-29 fragment

Sermorelin is [Tyr¹]-GHRH(1-29)-NH₂, the N-terminal 29 amino acids of human GHRH with a C-terminal amide. Sequence:

Y-A-D-A-I-F-T-N-S-Y-R-K-V-L-G-Q-L-S-A-R-K-L-L-Q-D-I-M-S-R-NH₂

Molecular formula C₁₄₉H₂₄₆N₄₄O₄₂S; molecular weight 3357.88 Da; monoisotopic mass 3355.88 Da.

The 1-29 fragment retains full biological activity relative to the full-length 1-44 parent because the C-terminal 30-44 region serves primarily as a helix-stabilising extension rather than as a direct receptor-engagement determinant. Systematic truncation studies from the 1980s established that the 1-29 fragment is the minimum biologically active unit with retained potency. This insight is the basis for all subsequent GHRH analogue design.

Comparison with downstream analogues:

• Sermorelin: GHRH(1-29), unmodified. Position 2 = Ala (DPP-4-cleavable). Half-life 10-20 min.
• CJC-1295 no-DAC: GHRH(1-29) with four substitutions — D-Ala², Gln⁸, Ala¹⁵, Leu²⁷. Position 2 = D-Ala (DPP-4-resistant). Half-life 25-30 min.
• CJC-1295 with DAC: Same as CJC-1295 no-DAC plus a C-terminal maleimidopropionyl-lysine tail for albumin conjugation. Half-life ~8 days as the albumin conjugate.
• Tesamorelin: Full-length GHRH(1-44) with trans-3-hexenoyl N-terminal modification. Half-life ~30-40 min.

3. GHRH receptor pharmacology

Sermorelin binds the GHRH receptor — a class B G-protein-coupled receptor expressed primarily on anterior pituitary somatotrophs — with affinity comparable to native GHRH(1-44). Signal transduction follows the standard class B GPCR pathway:

1. Gαs coupling on ligand binding
2. Adenylyl cyclase activation
3. Intracellular cAMP elevation
4. PKA activation
5. CREB phosphorylation
6. Transcriptional upregulation of GH1 (growth hormone gene)
7. GH vesicle exocytosis from somatotroph storage granules

Sermorelin also produces low-level intracellular Ca²⁺ mobilisation via Gαq coupling in some somatotroph populations — a feature shared with native GHRH and with all GHRH analogues, but mechanistically subordinate to the dominant cAMP-PKA pathway.

4. Pharmacokinetics and the 10-minute half-life

• Plasma half-life: 11-12 minutes (Merriam et al) with a typical range of 10-20 minutes quoted in the literature
• Tmax after SC injection: 5-20 minutes
• GH-releasing effect duration: 60-90 minutes per dose
• Bioavailability (SC vs IV): ~4-10%, reflecting rapid DPP-4 inactivation
• Primary inactivation: DPP-4 cleavage at Ala², producing inactive GHRH(3-29)
• Secondary inactivation: renal clearance of DPP-4-cleaved fragments
• No hepatic CYP metabolism

The 10-minute half-life is the single most important PK feature. It means sermorelin can only generate a sharp, isolated GH pulse — it cannot support sustained GHRH receptor engagement, and therefore cannot produce the tonic IGF-1 elevation that longer-acting analogues (CJC-1295 with DAC, tesamorelin) deliver.

5. Geref clinical history

Sermorelin acetate was approved by the FDA in 1997 as Geref (Serono) for treatment of idiopathic growth hormone deficiency in children. The approval was based on paediatric trials demonstrating sustained height velocity improvement over 12-36 months of daily subcutaneous administration.

Geref was commercially withdrawn from the US market in 2008, reportedly for commercial rather than safety or efficacy reasons — the parallel availability of recombinant human growth hormone (rhGH, Humatrope/Genotropin/Norditropin) had captured most of the paediatric GHD market, and sermorelin’s short-half-life daily dosing had become commercially uncompetitive. The molecule itself remains in regulatory files and can be referenced in investigational protocols.

For UK research, sermorelin remains available as a research-grade peptide with unchanged pharmacology.

6. Paediatric growth hormone deficiency trials

Key paediatric Geref-era data (pooled across multiple trials):

• Cohort: children with idiopathic GHD, baseline height SDS typically −2.5 to −3
• Dose: 1.0 µg/kg SC at bedtime
• Duration: 12-36 months
• Height velocity: typically 6-10 cm/year over 12-month observation, vs ~3-4 cm/year baseline
• IGF-1: rose from deficient baseline into the normal paediatric range
• IGFBP-3: similar pattern to IGF-1
• Safety: generally well tolerated; transient injection-site reactions and mild facial flushing most common

Sermorelin was less effective than rhGH for height-velocity outcomes, particularly in children with severe GHD (peak stimulated GH <5 ng/mL), because the sermorelin mechanism requires intact somatotroph reserve — children with severe hypothalamic or pituitary structural deficits cannot respond to GHRH receptor stimulation with adequate GH release. This explains the dominance of rhGH in that clinical space.

For research purposes, sermorelin remains a useful provocative agent in GH-axis testing protocols (e.g. sermorelin + arginine stimulation test) and as a mechanistic investigational tool.

7. Adult GH axis research

Sermorelin has been studied in adult populations in several research contexts:

• Somatopause research: Age-related decline in GH and IGF-1 is partially responsive to sermorelin 0.5-1 µg/kg at bedtime, with modest IGF-1 elevation over 4-12 weeks.
• Obesity and body composition: Small trials have shown modest favourable effects on body composition; effect magnitude is smaller than CJC-1295 with DAC or tesamorelin.
• Diagnostic provocative testing: Sermorelin alone or with arginine remains a validated diagnostic test for adult GHD in some international guidelines (less commonly used in current UK practice, where glucagon stimulation and insulin tolerance testing dominate).
• Sleep architecture research: Sermorelin administration at bedtime modestly enhances slow-wave sleep duration, consistent with the established association of GH pulses with slow-wave sleep.

8. Pulsatility preservation — the core research use

Sermorelin’s short half-life is simultaneously its primary limitation for clinical use and its primary advantage for research use. The 10-minute half-life means that a single SC injection produces a sharp, defined GH pulse that returns to baseline within 60-90 minutes. This recapitulates the natural GH pulse profile more faithfully than any longer-acting GHRH analogue.

Research applications where this property is valuable:

• Studying JAK2-STAT5 pulse-encoded signalling in hepatic or muscle target tissues
• Studying GH receptor desensitisation kinetics at physiological pulse intervals
• Studying sex-dimorphic GH pulse patterns in rodent models
• Modelling natural nocturnal GH pulsing with bedtime administration
• Pulsatility-sensitive gene expression studies (hepatic CYP450 isoforms, IGF-1 transcription in different tissues)

Modern pulsatility research increasingly uses CJC-1295 no-DAC (which retains adequate pulsatility with a more practical 25-30 minute half-life), but sermorelin remains the reference “native GHRH pulse” comparator.

9. Sermorelin vs CJC-1295 vs tesamorelin

A practical comparison for UK research protocol design:

Pulsatility preservation (sharp, isolated pulses):

• Sermorelin: best (native-like pulse)
• CJC-1295 no-DAC: very good (slightly broader pulse)
• Tesamorelin: good (modestly broader pulse)
• CJC-1295 with DAC: none (tonic)

Duration of GH-releasing effect per dose:

• Sermorelin: 60-90 min
• CJC-1295 no-DAC: 60-120 min
• Tesamorelin: 180-240 min
• CJC-1295 with DAC: continuous at steady state

IGF-1 elevation magnitude at maintenance:

• Sermorelin at 1 µg/kg daily: modest (15-30% above baseline)
• CJC-1295 no-DAC at 100 µg 2-3× daily: moderate (20-40%)
• Tesamorelin 2 mg daily: large (50-100%)
• CJC-1295 with DAC at 1-2 mg weekly: large (50-100%)

DPP-4 resistance:

• Sermorelin: no (Ala² cleaved rapidly)
• CJC-1295 (both forms): yes (D-Ala² substitution)
• Tesamorelin: yes (trans-3-hexenoyl N-terminal block)

10. Combined protocols with ghrelin-mimetics

The mechanistic synergy between GHRH analogues and ghrelin-receptor agonists is well-established (see our CJC-1295 + ipamorelin reference for detailed mechanism). Sermorelin can be substituted for CJC-1295 no-DAC in these combined protocols when native-like pulsatility is preferred:

• Sermorelin 200-300 µg + ipamorelin 200 µg SC, co-administered 1-3× daily
• Produces sharp, amplified GH pulse matching physiological pulse morphology
• Useful for pulsatility-sensitive mechanistic research
• Less practical than CJC-1295 no-DAC for longer study durations owing to higher injection frequency requirement

11. Safety profile and tolerability

Sermorelin has the longest accumulated safety record of any GHRH analogue, spanning >25 years of research and clinical use. Typical adverse events:

• Injection-site reactions: 15-20% (mild erythema, transient induration)
• Flushing: 5-10% (facial, transient, typically 5-15 min post-injection)
• Headache: 5-10%
• Dizziness: 2-5%
• Mild transient hyperglycaemia: <5% at standard doses
• Fluid retention: rare at standard doses (dose-dependent, more common at supra-physiological doses)
• Hypersensitivity reactions: rare (<0.1%)

Notable absences: no cortisol, prolactin or thyroid axis disruption (GHRH is selective for somatotrophs). No carcinogenicity signal in long-term paediatric follow-up. No clinically significant drug interactions identified.

12. Reconstitution, storage and stability

Sermorelin typically ships as lyophilised powder in 2 mg or 5 mg vials. Reconstitution:

• 2 mg vial: add 2 mL bacteriostatic water (0.9% benzyl alcohol preserved) → 1 mg/mL
• 5 mg vial: add 5 mL bacteriostatic water → 1 mg/mL

At 200-300 µg per administration, 0.2-0.3 mL (20-30 units on an insulin syringe). Post-reconstitution storage: 2-8°C, use within 30 days. Sermorelin is moderately susceptible to oxidation at the methionine residue (position 27); avoid prolonged room-temperature exposure and protect from direct light.

Aqueous stability at 2-8°C is slightly less robust than CJC-1295 analogues — sermorelin degradation products (principally oxidised Met and des-Ala-1-Tyr-1 species) accumulate more quickly owing to the absence of stabilising modifications.

13. Modern research protocol design

Typical UK laboratory research protocols using sermorelin:

• Pulsatility research: 200-300 µg SC, 1-3× daily at physiological pulse-mimicking intervals. Co-administration with ipamorelin 200 µg optional for pulse amplitude amplification.
• Bedtime GH axis research: 200-300 µg SC at bedtime, 8-12 week duration. Endpoint: nocturnal GH AUC and morning IGF-1.
• Diagnostic provocative testing: 1 µg/kg IV as bolus, GH sampling at 0, 15, 30, 45, 60, 90, 120 min. Peak GH >10 ng/mL is conventional cut-off for intact somatotroph reserve.
• Dose-response studies: 0.5, 1, 2, 4 µg/kg SC to establish individual dose-response curve; useful in mechanism-of-action studies.

Baseline measurements and monitoring follow the standard GHRH analogue protocol (see our CJC-1295 + ipamorelin and tesamorelin references for detailed monitoring recommendations).

14. UK research-grade sourcing standards

Sermorelin should be sourced with full documentation:

• ≥98% HPLC purity (≥99% is the emerging 2026 standard)
• Mass spectrometry identity confirmation (theoretical MW 3357.88 Da; monoisotopic 3355.88 Da)
• Batch-specific Certificate of Analysis
• Endotoxin quantification
• Residual TFA analysis (especially important for solid-phase-synthesised sermorelin)
• Oxidation state of Met27 (should be <1% sulfoxide)
• Lyophilised powder with cold-chain shipping

A quality-control specific note: sermorelin’s unprotected Ala² position makes the molecule susceptible to very rapid DPP-4 cleavage at any point during manufacturing, shipping, or handling where endogenous DPP-4 could be introduced. The COA should confirm absence of the DPP-4-cleaved GHRH(3-29) fragment — its presence at >1% indicates mishandling or contamination and would compromise in vivo bioactivity.

FAQ

Is sermorelin the same molecule as GHRH?
Sermorelin is the 1-29 N-terminal fragment of human GHRH. Native GHRH is 1-44. The 1-29 fragment retains full biological activity relative to 1-44, which is why sermorelin and tesamorelin (full-length) produce indistinguishable receptor engagement at equivalent molar doses.

Why is sermorelin’s half-life so short?
Unmodified Ala² at position 2 is the preferred DPP-4 cleavage site. The enzyme is ubiquitous in plasma, and cleavage at Ala²-Asp³ produces inactive GHRH(3-29). All subsequent GHRH analogues solve this with a position 2 substitution (CJC-1295: D-Ala²) or N-terminal blocking group (tesamorelin: trans-3-hexenoyl).

Has sermorelin been withdrawn from sale?
Geref (the commercial sermorelin acetate for injection product) was withdrawn from the US market in 2008 for commercial reasons — not safety or efficacy. The molecule itself has not been withdrawn from regulatory files. Sermorelin remains available as a research-grade peptide.

Is sermorelin safer than CJC-1295?
No meaningful safety difference has been established. Both produce standard GHRH-class adverse events (injection site, flushing, mild headache) at equivalent frequencies. Sermorelin has the longer accumulated safety database owing to its historical clinical use.

Why use sermorelin if CJC-1295 no-DAC is better in every practical respect?
For most applications, CJC-1295 no-DAC is preferred. Sermorelin retains niche research use: (1) native-like pulsatility research, (2) validated diagnostic provocative testing, (3) reference comparator in receptor pharmacology studies. For general IGF-1-elevation research, CJC-1295 or tesamorelin is the rational choice.

Can sermorelin be combined with ipamorelin?
Yes. The combination produces synergistic GH pulse amplification via the same mechanism as CJC-1295 + ipamorelin (convergent second-messenger pathways at the somatotroph plus hypothalamic somatostatin suppression). Sermorelin + ipamorelin is used when native-like pulsatility is preferred over longer-acting analogues.

What stimulation tests use sermorelin?
Sermorelin-arginine stimulation test is a validated adult GHD diagnostic protocol in some international guidelines. UK practice more commonly uses glucagon stimulation or insulin tolerance testing. Sermorelin provocative testing remains a useful research tool for assessing somatotroph reserve.

References

1. Thorner MO et al. Human pancreatic growth-hormone-releasing factor selectively stimulates growth-hormone secretion in man. Lancet 1983;1:24–28.
2. Merriam GR et al. Growth hormone-releasing hormone treatment in normal older men. J Anti Aging Med 2001;4:311–324.
3. Thorner MO et al. Long-term treatment of idiopathic growth hormone deficiency with sermorelin acetate. J Clin Endocrinol Metab 1995;80:3113–3121.
4. Grossman A et al. GHRH and somatostatin: analogues and clinical use. Clin Endocrinol 1988;29:341–361.
5. Kineman RD et al. Understanding the physiology of growth hormone-releasing hormone and growth hormone-releasing peptide action. Front Endocrinol 2011;2:24.
6. Khorram O et al. Effects of aging on the pulsatile secretion of growth hormone and its response to GHRH. J Clin Endocrinol Metab 1997;82:1472–1479.
7. Corpas E, Harman SM, Blackman MR. Human growth hormone and human aging. Endocr Rev 1993;14:20–39.
8. Bowers CY. History of the development of GH-releasing peptides and analogues. Growth Horm IGF Res 2012;22:221–231.
9. Aimaretti G et al. Usefulness of growth hormone (GH) secretagogues in the diagnosis of GH deficiency in adults. J Endocrinol Invest 2003;26:67–72.
10. Hartman ML et al. Pulsatility of growth hormone: evaluation and role of sermorelin in diagnostic testing. Endocrinol Metab Clin North Am 1992;21:729–744.

UK Research Cluster Hubs

• GLP-1 Research Hub
• Tirzepatide Hub
• Retatrutide Hub
• BPC-157 Research Hub
• TB-500 Research Hub
• Growth-Hormone Peptides Hub
• Research-Grade Buyer’s Guide

Disclaimer: All peptides referenced are sold strictly for in vitro laboratory research use. Not for human consumption, veterinary use, food additive, cosmetic, or household purpose. Nothing in this article is medical advice. UK researchers are responsible for compliance with the Human Medicines Regulations 2012 and Misuse of Drugs Regulations 2001 where applicable.